Skip to main content
[Preprint]. 2023 Aug 25:2023.02.13.528384. Originally published 2023 Feb 14. [Version 2] doi: 10.1101/2023.02.13.528384

Fig. 2: The MPC suppression markedly reduced several TCA cycle intermediates in LX2 cells treated with uniformly labeled 13C-glucose.

Fig. 2:

a, The effect of MPC shRNA on relative abundance of glycolytic end products in LX2 cells treated with uniformly labeled 13C-glucose isotope. b, MPC suppression in LX2 cells reduced the relative abundance of several TCA cycle metabolites. c, Schematic of TCA cycle alterations measured by metabolomic analyses of LX2 cells stably expressing shRNA against MPC2. Red arrows, decreased; blue arrows, unchanged (comparing MPC2 shRNA to scrambled shRNA) d, Incorporation of 13C-glucose into glycolytic and TCA cycle intermediates in LX2 cells. TGFβ-1 (5 ng/mL) added into media to activate LX2 cells. GAP, glyceraldehyde 3-phosphate; DHAP, dihydroxyacetone phosphate; αKG, alpha-ketoglutarate; ALT2, alanine transaminase 2. Data are expressed as mean ± SEM, relative to TGFβ-1-free cells expressing non-targeting shRNA (n= 3 or 6). *p < 0.05.